Balancing Costs and Clinical Outcomes: A Cost-effectiveness Study of PICC Types Across Chinese Healthcare Settings
Preprint
- 7 April 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Long-term intravenous therapies often necessitate the use of peripherally inserted central catheters (PICCs), and antimicrobial-coated PICCs have been introduced to minimize catheter-related infections. A decision-analytic cost-effectiveness model was developed from a societal perspective utilizing real-world data concerning PICC-related complications and costs from Class 3A hospitals and community hospital settings in China. The analysis compared the quality-adjusted life years (QALYs) for patients receiving antimicrobial-coated PICCs versus standard PICCs, with catheter-associated costs included. Incremental cost-effectiveness ratios (ICERs) were calculated in Chinese Yuan (¥) per QALY gained.Patients with antimicrobial-coated PICCs experienced slightly fewer complication-related events, leading to significantly lower costs for managing complications. In the Class 3A hospital setting, the average total cost per patient was lower with antimicrobial-coated PICCs (¥62,800) compared to standard PICCs (¥102,900), primarily due to reduced expenses for treating CLABSI and related unknown fever. The ICER demonstrated that the coated PICC was the dominant option, showing a negative ICER (cost-saving of approximately ¥4 million per QALY gained in the base-case Class 3A hospital scenario). In community hospital care scenarios, the cost advantage of antimicrobial-coated PICCs remained. Thus, the antimicrobial-coated PICC strategy was cost-saving, providing equal or improved health outcomes at lower costs in China's medical center and community hospital settings, making it a more efficient choice for long-term vascular access.Keywords
All Related Versions
This publication has 28 references indexed in Scilit:
- Do Quality-Adjusted Life Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness AnalysesValue in Health, 2024
- Developing Criteria for Health Economic Quality Evaluation ToolValue in Health, 2023
- Effectiveness and ost-efficacy of iuretics ome dministration via eripherally nserted entral enous atheter in atients with nd- tage eart ailureInternational Journal of Cardiology, 2022
- Central venous catheter–related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)Annals of Hematology, 2020
- Cost-Effectiveness Analysis and Decision Modelling: A Tutorial for CliniciansJournal of Clinical and Experimental Hepatology, 2020
- Antimicrobial-impregnated central venous catheters for prevention of neonatal bloodstream infection (PREVAIL): an open-label, parallel-group, pragmatic, randomised controlled trialThe Lancet Child & Adolescent Health, 2019
- Impact of mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) on central line-associated bloodstream infections (CLABSIs) in department of hematology at single university hospital in JapanJournal of Infection and Chemotherapy, 2018
- A comparative evaluation of antimicrobial coated versus nonantimicrobial coated peripherally inserted central catheters on associated outcomes: A randomized controlled trialAmerican Journal of Infection Control, 2016
- Statistical Issues in Economic Evaluations2014
- Reduction of catheter-related infections in neutropenic patients: a prospective controlled randomized trial using a chlorhexidine and silver sulfadiazine-impregnated central venous catheterAnnals of Hematology, 2004